ETON vs. ANIP, VERA, JANX, EVO, OCUL, MESO, TVTX, BGM, GPCR, and CVAC
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs. Its Competitors
Eton Pharmaceuticals (NASDAQ:ETON) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.
In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 5 mentions for Eton Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.63 beat Eton Pharmaceuticals' score of 0.44 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 16.0% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Eton Pharmaceuticals has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Eton Pharmaceuticals currently has a consensus price target of $29.67, suggesting a potential upside of 105.31%. ANI Pharmaceuticals has a consensus price target of $80.13, suggesting a potential upside of 22.72%. Given Eton Pharmaceuticals' higher probable upside, research analysts clearly believe Eton Pharmaceuticals is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has a net margin of -3.12% compared to Eton Pharmaceuticals' net margin of -9.49%. ANI Pharmaceuticals' return on equity of 21.35% beat Eton Pharmaceuticals' return on equity.
Eton Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats Eton Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 7/3/2025 by MarketBeat.com Staff
